FDA’s New ‘Site Engagement’ Program Aims To Avert Quality-Related Drug Shortages
US FDA office that surveils drug manufacturing facilities invites sites on the cusp of failure for “engagements” in which they talk about how to turn things around. The agency says there’s no pressure – these site engagements aren’t enforcement actions and they’re completely voluntary.
